Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Eng

• Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective.

Innate Pharma SA IPHIPHA ("Innate" or the "Company") announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective.

As announced on December 19, 2022, Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate's ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Under the terms of the agreement, Innate will receive 25m upfront payment and up to 1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.